EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Design, Synthesis, Biological Evaluation, and Molecular Modeling Studies of Novel 2‐Aminothiazole Derivatives as Potential FOXM1 Inhibitors for Triple‐Negative Breast Cancer Therapy and Structure‐Activity Relationship

Khaled A N Abusharkh, Venhar Çınar, Alper Onder iD, Merve Sıkık iD, Mustafa Guzel, Zuhal Hamurcu, Bulent Ozpolat iD, Mehmet Ay, Ferah Comert Onder iD

Drug Development Research · 2026

DOI: 10.1002/ddr.70296 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Drug Development Research, 2026. Verfasst von Khaled A N Abusharkh und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemistry, School of Graduate Studies, Çanakkale Onsekiz Mart University, Çanakkale, Türkiye. Hauptthemen laut MEDLINE: Forkhead Box Protein M1, Thiazoles, Triple Negative Breast Neoplasms, Antineoplastic Agents. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 61 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: The Scientific and Technological Research Council of Türkiye (TÜBİTAK) Project No. 221S682.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Triple Negative Breast Cancer (TNBC) is one of the most aggressive subtypes of breast cancer (BC), which is associated with a very poor prognosis. It is a broad category of tumors with a variety of biological, clinical, and morphological characteristics. FOXM1 is a pivotal transcription factor that modulates proliferation‐associated genes through complex protein‐DNA and protein‐protein interactions, making it a highly attractive target in cancer therapy. However, existing small‐molecule inhibitors often suffer from limited specificity and efficacy. In this study, we designed, synthesized, and evaluated novel series of 2‐aminothiazole derivatives ( C1‐C15) as potential FOXM1 inhibitors. Molecular docking and molecular dynamics (MD) simulations were employed to investigate the binding interactions of these compounds with the FOXM1 DNA‐binding domain (FOXM1‐DBD). Structural analysis highlighted the importance of crucial residues, including Asn283, His287, and Arg286, in mediating inhibitory activity. Among the synthesized compounds, C11 exhibited remarkable structural alignment and interaction patterns with FOXM1‐DBD, comparable to the reference inhibitor FDI‐6. In vitro studies using TNBC cell lines (MDA‐MB‐231, BT‐549, and BT‐20) demonstrated that compound C11 significantly outperformed FDI‐6 in potency. Western blot analysis revealed that C11 effectively suppressed FOXM1 transcriptional activity at concentrations of 10 µM in BT‐549 cells and 20 µM in MDA‐MB‐231 cells. These findings underscore the potential of C11 as a potent FOXM1 inhibitor and highlight its promise for further development in TNBC therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Forkhead Box Protein M1ThiazolesTriple Negative Breast NeoplasmsAntineoplastic AgentsHumansStructure-Activity RelationshipDrug DesignFemaleMolecular Docking SimulationCell Line, TumorMolecular Dynamics SimulationCell ProliferationMDA-MB-231 CellsModels, Molecular

Stichwörter der Autor:innen

2‐aminothiazoleFOXM1MD simulationsTNBCinhibitor

Substanzen

Forkhead Box Protein M1ThiazolesFOXM1 protein, human2-aminothiazoleAntineoplastic Agents

Autor:innen und Institutionen

  • Department of Chemistry, School of Graduate Studies, Çanakkale Onsekiz Mart University, Çanakkale, Türkiye.
  • Department of Chemistry, Natural Products and Drug Research Laboratory, Faculty of Science, Çanakkale Onsekiz Mart University, Çanakkale, Türkiye.
  • Department of Chemistry and Chemical Technology, Faculty of Science and Technology, Al-Quds University, Jerusalem, Palestine.
  • Department of Medical Biology, Faculty of Medicine, Erciyes University, Kayseri, Türkiye.
  • Department of Medical System Biology, School of Graduate Studies, Çanakkale Onsekiz Mart University, Çanakkale, Türkiye.
  • Research Institute for Health Sciences and Technologies (SABITA), Center of Drug Discovery and Development, Istanbul Medipol University, İstanbul, Türkiye.

ORCID-Profile: Alper Onder, Merve Sıkık, Bulent Ozpolat, Ferah Comert Onder

Förderung

  • The Scientific and Technological Research Council of Türkiye (TÜBİTAK) Project No. 221S682

Zitieren

APA

Abusharkh, K. A. N., Çınar, V., Onder, A., Sıkık, M., Mustafa Guzel, Hamurcu, Z., Ozpolat, B., Ay, M., & Comert Onder, F. (2026). Design, Synthesis, Biological Evaluation, and Molecular Modeling Studies of Novel 2‐Aminothiazole Derivatives as Potential FOXM1 Inhibitors for Triple‐Negative Breast Cancer Therapy and Structure‐Activity Relationship. Drug Development Research. https://doi.org/10.1002/ddr.70296

Vancouver

Abusharkh KAN, Çınar V, Onder A, Sıkık M, Mustafa Guzel, Hamurcu Z, et al. Design, Synthesis, Biological Evaluation, and Molecular Modeling Studies of Novel 2‐Aminothiazole Derivatives as Potential FOXM1 Inhibitors for Triple‐Negative Breast Cancer Therapy and Structure‐Activity Relationship. Drug Development Research. 2026. doi:10.1002/ddr.70296

BibTeX
@article{Abusharkh2026,
  author = {Abusharkh, Khaled A N and Çınar, Venhar and Onder, Alper and Sıkık, Merve and Mustafa Guzel and Hamurcu, Zuhal and Ozpolat, Bulent and Ay, Mehmet and Comert Onder, Ferah},
  title = {Design, Synthesis, Biological Evaluation, and Molecular Modeling Studies of Novel 2‐Aminothiazole Derivatives as Potential FOXM1 Inhibitors for Triple‐Negative Breast Cancer Therapy and Structure‐Activity Relationship},
  journal = {Drug Development Research},
  year = {2026},
  doi = {10.1002/ddr.70296}
}
Kostenlos starten →